Oncology Nurses Must Observe for CAR T-Cell Therapy Side Effects
It is increasingly significant that oncology nurses and other healthcare providers recognize cytokine release syndrome (CRS) and other side effects that can be triggered by anticancer treatment with engineered chimeric antigen receptor (CAR) T-cell therapies, and that they understand the importance of early detection, a speaker emphasized at the Oncology Nursing Society (ONS) 42nd Annual Congress, held May 4–7 in Denver.
“Careful monitoring is essential for early detection of CAR T-cell side effects,” said examine coauthor Brenna Hansen, BSN, RN, OCN, a research nurse specialist at the Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. “Early recognition of symptoms results in early intervention and safe management of the patient by the multidisciplinary team.”
CAR T-cell therapy involves equipping immune T cells with engineered receptors to facilitate immune attack on tumor cells voicing specific surface proteins. Patient T cells are collected and modified in a lab to express cancer-specific receptors. These are then infused back into the patient.
CAR T-cell therapies demonstrate promise against hematologic malignancies and other cancers but can trigger a range of primarily subtle but potentially life-threatening side effects. Perhaps chief among these adverse reactions is CRS and neurologic side effects that might or might not occur with CRS. Most of these are reversible with corticosteroids or other treatment.
CRS symptoms include fever, tachycardia, and hypotension occurring within a week (typically 4–7 days) after CAR T-cell infusion, however CRS can occur more quickly. “I’ve seen CRS as soon as a day after infusion,” Hansen cautioned.
Heart arrhythmias, tiredness, hypoxia, pulmonary edema, pneumonitis, electrolyte imbalances, nausea, vomiting, diarrhea, cytopenias, infections, elevated creatinine kinase, myalgia, and muscle weakness can all be signs of CRS.
Neurologic side effects can include tremors, headaches, confusion, loss of balance, trouble speaking, encephalopathy, seizures, long periods of somnolence, and sometimes, hallucinations, Hansen noted.
These symptoms can be subtle originally. Hansen described a CAR T-cell therapy patient’s transportation by ambulance to the hospital after detection of a subtle forearm tremor because clinicians were worried it could quickly worsen.
CAR T-cell therapies can also trigger receptor/cell-type specific side effects such as CAR19-associated B-cell aplasia and graft-vs-host disease. Fresh side effects will likely emerge as fresh targets are found and CAR T-cell therapies become more commonly administered, she predicted.
Nurses play key roles in every stage of CAR T-cell toxicity monitoring and management, from inpatient monitoring at the bedside, including frequent assessments and checks of vital signs during high-risk periods, to outpatient and long-term monitoring, Hansen said.
Outpatient monitoring for patients who are infused as outpatients, or post-discharge, is key to spotting delayed toxicities, she emphasized. Clinic and triage nurses play key roles in the timely recognition of late CAR T-cell side effects.
Long-term monitoring is significant, as well. Home oncology clinic nurses should monitor serum IgG (IVIG) and blood cell counts with differential.
“If symptoms become severe, cells may be tempered with tocilizumab or corticosteroids,” she said. “However, this is avoided if possible to prevent hurting the anti-malignancy effects of the CAR T cells.”
It is crucial that nursing staff be educated on side effects unique to CAR T-cell treatments, and that nursing guidance be provided specifying the signs and symptoms that should be communicated to patients’ other healthcare providers—and patients themselves—to permit early detection and intervention. “Having a written plan can help prevent confusion and provide clear guidelines for the patient’s care,” she noted.
